COVID-19 Vaccines: Global Market Trajectory & Analytics

Strategic Insights -

As the world grapples with the emergence of new COVID-19 variants, a new market study published by Global Industry Analysts Inc. (GIA) sheds light on the global market trajectory and analytics of COVID-19 vaccines. The report presents fresh perspectives on opportunities and challenges in a significantly transformed post-COVID-19 marketplace. The emergence of the Omicron variant, with over 50 mutations, has further complicated the pandemic management landscape, threatening to reduce vaccine effectiveness by 40-50% and potentially outsmarting monoclonal antibodies. With Europe battling fourth and fifth waves of infections, the world is up against a new challenge in the war against the virus.

Key Takeaways:

  • The Omicron variant has over 50 mutations, with 32 on its spike protein, making it more transmissible and potentially vaccine-resistant.
  • The variant has been detected in Asia, Europe, and North America, with cases spiking in several countries.
  • Lockdowns, travel restrictions, and mask mandates are expected to be reinstated if the Omicron variant is not controlled.
  • The speed of vaccine administration must be accelerated to end the pandemic, with mass vaccination drives required to outpace viral mutation.
  • Booster shots are being developed by leading vaccine makers to address emerging threats from new variants, with mRNA-vaccines from Pfizer/BioNTech and Moderna expected to be used as booster shots in some countries.
  • Moderna has announced positive initial data from its ongoing phase 2 study on a variant-specific booster shot, with studies showing that a third dose can boost antibodies even in immunocompromised patients.
  • Vaccine tweaking and updating with new spike proteins is necessary to prepare for new variants, but this process requires additional clinical trials, more time-consuming research work, and regulatory approvals.
  • Rapid mass vaccinations are necessary to limit the spread of mutant strains, but vaccines themselves contribute to virus mutations.
  • To end the pandemic, more focus is required on vaccine equality, international cooperation in COVID research, transparent information transfer, and science-based swift decisions regarding travel bans.

Statistics:

  • 40-60% increase in transmissibility of the Omicron variant compared to the Alpha variant.
  • 32 mutations on the spike protein of the Omicron variant.
  • 50 mutations in total on the Omicron variant.
  • 40-50% reduction in vaccine effectiveness against the Omicron variant.
  • 67,000+ domain experts worldwide using the MarketGlass(TM) Platform.
  • 42,000+ clients from 36 countries served by GIA.

Sources:

  • Global Industry Analysts Inc. (GIA), "COVID-19 Vaccines - Global Market Trajectory & Analytics" (December 2021)
  • Global Industry Analysts Inc. (GIA), MarketGlass(TM) Platform
  • Global Industry Analysts Inc. (GIA), StrategyR.com